Session Details

Oral Oresentation 3

Fri. Jul 11, 2025 2:00 PM - 3:15 PM JST
Fri. Jul 11, 2025 5:00 AM - 6:15 AM UTC
Room Ⅲ(Makuhari Messe Meeting Room 201)
Chair:Ryuichi Okamoto, Shigeki Bamba

[O03-01]PROFILE: endoscopic outcomes from a randomized controlled trial of treatment strategies in newly-diagnosed Crohn's disease

*Nurulamin Noor1, PROFILE Study Group (1. University of Cambridge)
Comment()

[O03-02]Comparison of clinical efficacy among ulcerative colitis patients treated with infliximab, vedolizumab, and ustekinumab as a first-line biologics: Evaluation based on adapted Mayo score

*Makoto Naganuma1, Hisashi Shiga2, Minoru Matsuura3, Kento Takenaka4, Toshimitsu Fujii4, Shojiro Yamamoto5, Mao Matsubayashi6,7, Taku Kobayashi7, Tadakazu Hisamatsu3, UC-Bio Study Group (1. Third Department of Internal Medicine, Kansai Medical University, 2. Division of Gastroenterology, Tohoku University Graduate School of Medicine, 3. Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, 4. Department of Gastroenterology and Hepatology, Institute of Science Tokyo, 5. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 6. Inflammatory Bowel Disease Center, Yokohama City University Medical Center, 7. Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital)
Comment()

[O03-03]A Multicenter, Randomized Controlled Trial on the Efficacy and Safety of Vedolizumab in Combination with Upadacitinib for Moderate-to-Severe Ulcerative Colitis

Hongzhen Wu1, Tao Su1, Luying Wu1, Min Zhi1, *Jiayin Yao1 (1. Sun Yat-sen University Sixth Affiliated Hospital)
Comment()

[O03-04]High clinical and endoscopic remission rate with Vedolizumab in early CD patients: the 2nd interim analysis from a prospective multicenter interventional study (EARLY CD)

*Jing Liu1,2, Hong Guo3, Yuqin Li4, Liangru Zhu 5, Yan Jia6, Hongjie Zhang7, Heng Zhang8, Qin Huang9,10, Xiang Gao11, Qian Cao1,2 (1. Sir Run Run Shaw Hospital- Zhejiang University School of Medicine, Department of Gastroenterology, Hangzhou, China., 2. Sir Run Run Shaw Hospital- Zhejiang University School of Medicine, Inflammatory Bowel Disease Center, Hangzhou, China., 3. Chongqing General Hospital- Chongqing University, Department of Gastroenterology, Chongqing, China., 4. First Hospital of Jilin University, Department of Gastroenterology, Changchun, China., 5. Union Hospital- Tongji Medical College- Huazhong University of Science and Technology, Department of Gastroenterology, Wuhan, China., 6. Seventh Medical Center of PLA General Hospital, Department of Gastroenterology, Beijing, China., 7. The First Affiliated Hospital with Nanjing Medical University, Department of Gastroenterology, Nanjing, China., 8. The Central Hospital of Wuhan- Tongji Medical College- Huazhong University of Science and Technology, Department of Gastroenterology, Wuhan, China., 9. Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Department of Gastroenterology, Taizhou, China., 10. Enze Hospital-Taizhou Enze Medical Center Group, Department of Gastroenterology, Taizhou, China., 11. The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China.)
Comment()

[O03-05]Clinical effectiveness of Vedolizumab in Chinese patients for ulcerative colitis: interim results from the VALUE study

Yan Chen1, Yihong Fan2, Xiaoyu Qian3, *Li Xie3, Minhu Chen4 (1. The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China 310000, 2. Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, China 310008, 3. Takeda Pharmaceutical Company, Shanghai, China,100027, 4. The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,510080)
Comment()

[O03-06]Clinical effectiveness of Vedolizumab in Chinese patients with Crohn's Disease: interim results from the VALUE study

Li Li1, Xiaoqi Zhang2, Yaqiu Hu3, *Li Xie3, Minhu Chen1 (1. The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 510080, 2. Nanjing Drum Tower hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing China,210003, 3. Takeda Pharmaceutical Company, Shanghai, China, 200126)
Comment()

[O03-07]Real-world experience of switching from intravenous to subcutaneous vedolizumab in Korean patients with inflammatory bowel disease

*Yu Kyung Jun1,2, Yonghoon Choi1, Cheol Min Shin1,2, Young Soo Park1, Nayoung Kim1,2, Dong Ho Lee1,2, Sung Wook Hwang3, Hyuk Yoon1,2 (1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, 2. Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea, 3. Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea)
Comment()

[O03-08]VALIDATION OF THE V-CDST IN PATIENTS WITH CROHN’S DISEASE STARTING VEDOLIZUMAB IN HONG KONG

*Wai Keung Leung1, Yan Yan Guo1, Joyce Mak2, Siew Chien Ng2, Ka Shing Michael Cheung1 (1. The University of Hong Kong, 2. The Chinese University of Hong Kong)
Comment()

[O03-09]A Clinical Study on the Optimization of Vedolizumab Induction Therapy for Moderate to Severe Active Ulcerative Colitis at Week 10

*Manning Li1, Ying Xie1, Feng Tian1 (1. Department of Gastroenterology, Shengjing Hospital of China Medical University)
Comment()

[O03-10]Clinical study of Five-flavor sophora flavescens enteric-coated capsules combined with vedolizumab in the induction treatment of ulcerative colitis

*Xinglang Li1, Ying Xie1, Feng Tian1 (1. Shengjing Hospital of China Medical University, Department of Gastroenterology, Shenyang , Liaoning Province, China)
Comment()

[O03-11]Efficacy of Etrolizumab in Moderately-Severe Ulcerative Colitis with Previous Anti-TNF Use : A Systematic Review & Meta Analysis of Randomized Clinical Trials

*Jonathan Bryan Lee1, Jonathan Vincent Lee2, Mario Sutanto2 (1. Faculty of Medicine, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia, 2. Faculty of Medicine, University of Pelita Harapan, Tangerang, Indonesia)
Comment()

[23024-34-12add]Oral Presentaion

Comment()